Ikoma Naruhiko, Torres Keila E, Lin Heather Y, Ravi Vinod, Roland Christina L, Mann Gary N, Hunt Kelly K, Cormier Janice N, Feig Barry W
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Surg Oncol. 2017 Sep;116(3):313-319. doi: 10.1002/jso.24667. Epub 2017 May 29.
Optimal treatment strategies for retroperitoneal leiomyosarcoma (RPLMS), particularly recurrent disease, are unknown.
We searched the tumor registry at The University of Texas MD Anderson Cancer Center (MDACC) to identify patients with RPLMS treated between 1994 and 2013.
We identified 172 patients with a diagnosis of a RPLMS. Among the 85 patients who underwent complete resection included in the survival analysis, the median overall survival (OS) was 8.3 years (95% confidence interval [CI], 5.7-12.3), 5-year local recurrence rate was 21%, and 5-year distant metastasis rate was 47%. Among 114 patients who experienced recurrence, patients who underwent salvage surgery for recurrent disease had longer OS after recurrence than patients who did not undergo salvage surgery (median survival after recurrence 5.6 vs 3.3 years, 3-year OS rates after recurrence 72.6% vs 58.1%, HR 0.402 [95%CI, 0.243-0.666]; P = 0.0004). Whether salvage surgery was performed for local or distant recurrence was not associated with OS. Patients who had a longer disease-free interval (≥12 months) had better progression-free survival after salvage surgery than those who had a shorter interval (HR, 0.437 [95%CI, 0.244-0.783]; P = 0.0055).
We recommend that salvage surgery be considered for selected patients with local or distant recurrence of RP LMS.
腹膜后平滑肌肉瘤(RPLMS)的最佳治疗策略,尤其是复发性疾病的治疗策略尚不清楚。
我们检索了德克萨斯大学MD安德森癌症中心(MDACC)的肿瘤登记处,以确定1994年至2013年间接受治疗的RPLMS患者。
我们确定了172例诊断为RPLMS的患者。在生存分析中纳入的85例接受了完整切除的患者中,中位总生存期(OS)为8.3年(95%置信区间[CI],5.7 - 12.3),5年局部复发率为21%,5年远处转移率为47%。在114例复发的患者中,接受复发性疾病挽救性手术的患者复发后的总生存期比未接受挽救性手术的患者更长(复发后的中位生存期分别为5.6年和3.3年,复发后3年总生存率分别为72.6%和58.1%,风险比0.402[95%CI,0.243 - 0.666];P = 0.0004)。挽救性手术是针对局部复发还是远处复发进行的与总生存期无关。无病间期较长(≥12个月)的患者在接受挽救性手术后的无进展生存期比无病间期较短的患者更好(风险比,0.437[95%CI,0.244 - 0.783];P = 0.0055)。
我们建议对于部分局部或远处复发的RPLMS患者考虑进行挽救性手术。